The potential of nicotinic enhancement of cognitive remediation training in schizophrenia (Q38019281)

27 August 2017

title

The potential of nicotinic enhancement of cognitive remediation training in schizophrenia (English)

1 reference

27 August 2017

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22705396

cognitive behavioral therapy

4 January 2025

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22705396

4 January 2025

3

Robert W Buchanan

1 reference

27 August 2017

Britta Hahn

1

1 reference

27 August 2017

James M. Gold

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22705396

4 January 2025

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22705396

4 January 2025

publication date

13 June 2012

1 reference

full work available at URL

27 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0028390812002584?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

https://api.elsevier.com/content/article/PII:S0028390812002584?httpAccept=text/plain

4 January 2025

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

4 January 2025

1 reference

27 August 2017

volume

64

1 reference

27 August 2017

page(s)

185-190

1 reference

Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats

27 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Evidence for a role of nicotinic acetylcholine receptors in schizophrenia

4 January 2025

2

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia

4 January 2025

3

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia

4 January 2025

4

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial

4 January 2025

5

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls

4 January 2025

6

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Neurocognitive enhancement therapy with work therapy: effects on neuropsychological test performance

4 January 2025

7

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance

4 January 2025

8

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients

4 January 2025

9

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance

4 January 2025

10

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Immediate and Sustained Improvements in Working Memory After Selective Stimulation of α7 Nicotinic Acetylcholine Receptors

4 January 2025

11

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Oral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, Part I.

4 January 2025

12

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Lesions of the Basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning

4 January 2025

13

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings

4 January 2025

14

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system

4 January 2025

15

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study

4 January 2025

16

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

4 January 2025

17

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial

4 January 2025

18

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial

4 January 2025

19

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Light up and see: enhancement of the visual mismatch negativity (vMMN) by nicotine

4 January 2025

20

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia

4 January 2025

21

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later

4 January 2025

22

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus

4 January 2025

24

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Initial phase 2 trial of a nicotinic agonist in schizophrenia

4 January 2025

25

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

4 January 2025

26

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of smoking abstinence on visuospatial working memory function in schizophrenia

4 January 2025

27

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration

4 January 2025

28

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study

4 January 2025

29

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

4 January 2025

30

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Structural and functional diversity of native brain neuronal nicotinic receptors

4 January 2025

31

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement.

4 January 2025

32

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

What are the functional consequences of neurocognitive deficits in schizophrenia?

4 January 2025

33

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

4 January 2025

34

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands

4 January 2025

35

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task

4 January 2025

36

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Attentional effects of nicotinic agonists in rats

4 January 2025

37

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of dopamine receptor antagonists on nicotine-induced attentional enhancement

4 January 2025

38

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands

4 January 2025

39

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement

4 January 2025

40

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine-induced attentional enhancement in rats: effects of chronic exposure to nicotine

4 January 2025

41

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists.

4 January 2025

42

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine induces long-lasting potentiation in the dentate gyrus of nicotine-primed rats.

4 January 2025

43

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

The role of acetylcholine in learning and memory

4 January 2025

44

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Prefrontal cortical changes following cognitive training in patients with chronic schizophrenia: effects of practice, generalization, and specificity.

4 January 2025

45

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers

4 January 2025

46

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Meta-analysis of the acute effects of nicotine and smoking on human performance.

4 January 2025

47

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine delivery kinetics and abuse liability

4 January 2025

49

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior

4 January 2025

50

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder

4 January 2025

51

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Subjective effects of the nicotine lozenge: assessment of abuse liability

4 January 2025

52

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of abstinence from tobacco: valid symptoms and time course

4 January 2025

53

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia

4 January 2025

54

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Panmodal processing imprecision as a basis for dysfunction of transient memory storage systems in schizophrenia

4 January 2025

55

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

The pharmacology of cocaine related to its abuse

4 January 2025

56

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia

4 January 2025

57

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Phonetic mismatch negativity predicts verbal memory deficits in schizophrenia

4 January 2025

58

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Altering cortical connectivity: remediation-induced changes in the white matter of poor readers

4 January 2025

59

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine

4 January 2025

60

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Differential effects of nicotine on P50 amplitude, its gating, and their neural sources in low and high suppressors

4 January 2025

61

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Stimulant drugs and vigilance performance: a review

4 January 2025

62

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Phoneme discrimination in schizophrenia

4 January 2025

63

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine reduces antisaccade errors in task impaired schizophrenic subjects

4 January 2025

64

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Improving treatment for persons with schizophrenia

4 January 2025

65

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

A low dose of subcutaneous nicotine improves information processing in non-smokers

4 January 2025

66

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits

4 January 2025

67

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Getting the cue: sensory contributions to auditory emotion recognition impairments in schizophrenia

4 January 2025

68

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia

4 January 2025

69

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotinic receptor subtypes and cognitive function

4 January 2025

70

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Transdermal nicotine effects on attention

4 January 2025

71

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

4 January 2025

72

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia

4 January 2025

73

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

4 January 2025

74

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas

4 January 2025

75

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Schizophrenia and the alpha7 nicotinic acetylcholine receptor

4 January 2025

76

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

4 January 2025

77

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Differential sustained attention/vigilance changes over time in schizophrenics and controls during a degraded stimulus Continuous Performance Test

4 January 2025

78

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus

4 January 2025

79

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

A meta-analysis of cognitive remediation in schizophrenia

4 January 2025

80

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Cognitive Remediation in Schizophrenia

4 January 2025

81

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Choline and acetylcholine have similar kinetic properties of activation and desensitization on the alpha7 nicotinic receptors in rat hippocampal neurons

4 January 2025

82

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers

4 January 2025

83

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine improves delayed recognition in schizophrenic patients

4 January 2025

84

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review

4 January 2025

85

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Improvement of performance on an attention task with chronic nicotine treatment in rats

4 January 2025

86

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Chronic nicotine treatment in rats. 1. Acquisition and performance of an attention task

4 January 2025

87

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Measurement of visual sustained attention in schizophrenia using signal detection analysis and a newly developed computerized CPT task

4 January 2025

88

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of nicotinic stimulation on cognitive performance

4 January 2025

89

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

4 January 2025

90

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists

4 January 2025

91

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma

4 January 2025

93

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

An investigation into the effects of nicotine gum on short-term memory

4 January 2025

94

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Vigilance in schizophrenia and its disruption by impaired pre-attentive selection: a dysintegration hypothesis

4 January 2025

95

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Different effects of ionotropic and metabotropic glutamate receptor antagonists on attention and the attentional properties of nicotine

4 January 2025

96

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists

4 January 2025

97

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review

4 January 2025

98

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms

4 January 2025

99

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Muscarinic agonists for the treatment of cognition in schizophrenia

4 January 2025

100

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Effects of nicotine nasal spray on cognitive function in schizophrenia

4 January 2025

101

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2.

4 January 2025

102

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Inter-species consistency in the behavioural pharmacology of nicotine dependence

4 January 2025

103

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotine psychopharmacology: addiction, cognition and neuroadaptation

4 January 2025

104

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Computerized Cognitive Training Restores Neural Activity within the Reality Monitoring Network in Schizophrenia

4 January 2025

105

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Profile of cognitive problems in schizophrenia and implications for vocational functioning

4 January 2025

106

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

4 January 2025

107

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Neural deficits in children with dyslexia ameliorated by behavioral remediation: evidence from functional MRI.

4 January 2025

108

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of alpha7 receptors

4 January 2025

109

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

A review of cognitive training in schizophrenia

4 January 2025

110

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies

4 January 2025

111

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Hearing a voice in the noise: auditory hallucinations and speech perception

4 January 2025

112

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia

4 January 2025

113

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Reinforcing effect as a function of infusion speed in intravenous self-administration of nicotine in rhesus monkeys

4 January 2025

114

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease

4 January 2025

115

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters.

4 January 2025

116

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Talent in the taxi: a model system for exploring expertise

4 January 2025

117

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas.

4 January 2025

118

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Prepulse inhibition deficits in schizophrenia are modified by smoking status

4 January 2025

119

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

Polypharmacy in schizophrenia

4 January 2025

120

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.05.050

4 January 2025

Identifiers

1 reference

27 August 2017

1 reference